FDA approves the first treatment for nasopharyngeal carcinoma, a rare cancer that originates in the nasopharynx. The drug (toripalimab-tpzi) is a next-generation, programmed death receptor-1 monoclonal antibody. Because of the tumor's location (behind the nose), surgery is not usually an option.
Domestic Cat Nose Functions as Highly Efficient Gas Chromatograph, Says New Study
